Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05013905 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease
A Phase 2 study of Crohn Disease, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 2
- Development phase
- 55
- Enrollment target
- 20
- Study locations
NCT05013905: Completed Phase 2 study of Crohn Disease, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
NCT05013905 is a Phase 2 study of Crohn Disease that has completed, run by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 55 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05013905, a Phase 2 study of Crohn Disease, has completed, sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 55 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the safety and efficacy of PRA023 in participants with moderately to severely active Crohn's Disease. After the completion of the 12-week induction period, all participants have the option to continue in the open-label extension for another 38 weeks.
Primary Outcome
Number of participants who experienced treatment-emergent adverse events (AEs)
Conditions Studied
Interventions
- DRUG PRA023 IV
- DEVICE Companion diagnostic (CDx)
Study Locations (20)
Texas
- Prometheus Biosciences Selected Site - Garland
- Prometheus Biosciences Selected Site - Lubbock
- Prometheus Biosciences Selected Site - Lubbock
- Prometheus Biosciences Selected Site - San Antonio
- Prometheus Biosciences Selected Site - Southlake
- Prometheus Biosciences Selected Site - Tyler
California
- Prometheus Biosciences Selected Site - Los Angeles
- Prometheus Biosciences Selected Site - Los Angeles
Michigan
- Prometheus Biosciences Selected Site - Chesterfield
- Prometheus Biosciences Selected Site - Ypsilanti
Washington
- Prometheus Biosciences Selected Site - Bellevue
- Prometheus Biosciences Selected Site - Tacoma
Kansas
- Prometheus Biosciences Selected Site - Liberty
Missouri
- Prometheus Biosciences Selected Site - St Louis
New Hampshire
- Prometheus Biosciences Selected Site - Lebanon
New York
- Prometheus Biosciences Selected Site - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2021-07-28 |
| Est. Completion | 2025-05-27 |
| Phase | Phase 2 |
Sponsor
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)6 total trials
What the finished NCT05013905 record still lists
NCT05013905 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Crohn Disease appearing as the primary indexed condition, and to 2 interventions - of which PRA023 IV is the first listed.
NCT05013905 names 20 study sites across 12 states, led by Texas, California, Michigan.
Frequently Asked Questions
What is clinical trial NCT05013905 about?
NCT05013905 is a clinical study titled "A Phase 2a Safety and Efficacy Open-Label Study of PRA023 in Subjects With Moderately to Severely Active Crohn's Disease". The purpose of this study is to assess the safety and efficacy of PRA023 in participants with moderately to severely active Crohn's Disease. After the completion of the 12-week induction period, all participants have the option to continue in the open-label extension for another 38 weeks.
What is the current status of trial NCT05013905?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 55 participants. The study started on 2021-07-28. Estimated completion is 2025-05-27.
What conditions does trial NCT05013905 study?
This clinical trial studies the following conditions: Crohn Disease.
What interventions are being tested in trial NCT05013905?
The interventions under investigation include: PRA023 IV (DRUG), Companion diagnostic (CDx) (DEVICE).
Who is sponsoring clinical trial NCT05013905?
This trial is sponsored by Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05013905 being conducted?
This trial has 20 study locations across California, Kansas, Michigan, Missouri, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Crohn Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05013905's enrollment target sits among peer trials
55 45th of 71 higher than 25 of 71 other Crohn Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Standardized Microbiota Transplant Therapy in Crohn's Disease
RECRUITING · Phase 2
-
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RECRUITING · Phase 2
-
Precise Infliximab Exposure and Pharmacodynamic Control
RECRUITING · Phase 2
-
Autologous Stem Cell Transplant for Crohn's Disease
RECRUITING · Phase 2
-
A Study to Evaluate the Long-Term Effect of TEV-48574 in Moderate to Severe Ulcerative Colitis or Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI